company background image
2179 logo

Jiangsu Recbio Technology SEHK:2179 Stock Report

Last Price

HK$8.29

Market Cap

HK$4.0b

7D

-0.1%

1Y

-12.6%

Updated

01 Feb, 2025

Data

Company Financials +

Jiangsu Recbio Technology Co., Ltd.

SEHK:2179 Stock Report

Market Cap: HK$4.0b

2179 Stock Overview

A vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. More details

2179 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Jiangsu Recbio Technology Co., Ltd. Competitors

HBM Holdings

SEHK:2142

HK$2.7b

Ascentage Pharma Group International

SEHK:6855

HK$11.5b

TOT BIOPHARM International

SEHK:1875

HK$1.5b

Alphamab Oncology

SEHK:9966

HK$3.1b

Price History & Performance

Summary of share price highs, lows and changes for Jiangsu Recbio Technology
Historical stock prices
Current Share PriceHK$8.29
52 Week HighHK$9.97
52 Week LowHK$7.30
Beta-0.28
1 Month Change-11.15%
3 Month Change0.85%
1 Year Change-12.64%
3 Year Changen/a
5 Year Changen/a
Change since IPO-67.17%

Recent News & Updates

Jiangsu Recbio Technology (HKG:2179) Is Making Moderate Use Of Debt

Aug 23
Jiangsu Recbio Technology (HKG:2179) Is Making Moderate Use Of Debt

Recent updates

Jiangsu Recbio Technology (HKG:2179) Is Making Moderate Use Of Debt

Aug 23
Jiangsu Recbio Technology (HKG:2179) Is Making Moderate Use Of Debt

Does Jiangsu Recbio Technology (HKG:2179) Have A Healthy Balance Sheet?

Mar 26
Does Jiangsu Recbio Technology (HKG:2179) Have A Healthy Balance Sheet?

Shareholder Returns

2179HK BiotechsHK Market
7D-0.1%-1.2%0.4%
1Y-12.6%15.5%24.4%

Return vs Industry: 2179 underperformed the Hong Kong Biotechs industry which returned 10.8% over the past year.

Return vs Market: 2179 underperformed the Hong Kong Market which returned 24.2% over the past year.

Price Volatility

Is 2179's price volatile compared to industry and market?
2179 volatility
2179 Average Weekly Movement5.3%
Biotechs Industry Average Movement7.9%
Market Average Movement6.4%
10% most volatile stocks in HK Market13.9%
10% least volatile stocks in HK Market3.0%

Stable Share Price: 2179 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2179's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011507Yong Liuwww.recbio.cn

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage.

Jiangsu Recbio Technology Co., Ltd. Fundamentals Summary

How do Jiangsu Recbio Technology's earnings and revenue compare to its market cap?
2179 fundamental statistics
Market capHK$3.97b
Earnings (TTM)-HK$589.50m
Revenue (TTM)HK$46.64m

85.2x

P/S Ratio

-6.7x

P/E Ratio

Is 2179 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2179 income statement (TTM)
RevenueCN¥43.40m
Cost of RevenueCN¥17.09m
Gross ProfitCN¥26.31m
Other ExpensesCN¥574.86m
Earnings-CN¥548.54m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.14
Gross Margin60.63%
Net Profit Margin-1,263.92%
Debt/Equity Ratio81.5%

How did 2179 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 18:07
End of Day Share Price 2025/01/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Recbio Technology Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCMB International Securities Limited
Sean WuMorgan Stanley
Youjue HuMorgan Stanley